Paige Analysis: $100M Raised
What is Paige?
Paige builds software that advances the diagnosis, treatment, and biomarker discovery for cancer. Their approach integrates computational pathology to enhance diagnostic accuracy and efficiency. This technology transforms the workflow of pathologists, enabling more informed treatment decisions for patients.
Employees
51-200
Founded
2018
Industry
HealthTech, AI/ML, Biotech
Product Features & Capabilities
- Computational pathology software for enhanced diagnostic accuracy
- AI-driven insights for treatment decision-making
- FDA breakthrough designation for computational pathology products
- Intuitive user interface designed for pathologists
- Lightweight platform minimizing IT burden and costs.
Use Cases
Improve diagnostic confidence in cancer pathology; Streamline workflow for pathologists; Enhance treatment decision-making for cancer patients; Facilitate biomarker discovery for personalized medicine; Support data privacy and patient safety in diagnostics.
How much Paige raised
1 - $100 million
January 14, 2021Lead Investor: Casdin Capital, Johnson & Johnson Innovation – JJDC, Inc.
Other Considerations
Acquired by Tempus for $81.3M in 2025; First company to receive FDA breakthrough designation for computational pathology; Founded by experts from Memorial Sloan Kettering Cancer Center.
See something that needs updating? Suggest edits to this profile.